IRadimed Corporation carries no debt; cash flow comfortably covers obligations.

IRadimed Corporation's free cash flow has decreased 2.48% from $17.62M last year to $17.18M, signaling decreasing performance

IRadimed Corporation's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

IRadimed Corporation's debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

IRadimed Corporation has a net cash position, so leverage is healthy.

IRadimed Corporation carries no debt; interest obligations are fully covered.

IRadimed Corporation's profit margin has increased (1.68%) in the last year from 26.26% to 26.70%, signaling increasing performance

IRadimed Corporation's short-term assets of $81.20M exceed its short-term liabilities of $10.18M

IRadimed Corporation's return on assets of 20.05% is higher than the 5.00% threshold, indicating efficient asset utilization

IRadimed Corporation's return on equity of 23.45%, is higher than 15.00%, indicating good performance

IRadimed Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

IRadimed Corporation had positive net income in 5 out of 5 years, indicating stable and consistent earnings

IRadimed Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

IRadimed Corporation has a free cash flow yield of 1.49%, which is below the 2.00% threshold, indicating limited cash return relative to market value

IRadimed Corporation's yearly earnings has increased 16.88% since last year from $19.23M to $22.48M, signaling increasing performance

IRadimed Corporation's yearly revenue has increased 14.43% since last year from $73.24M to $83.81M, signaling increasing performance

ROIC 20.18% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

IRadimed Corporation's 3-year revenue CAGR of 16.28% is positive, indicating growing revenue over the past 3 years

IRadimed Corporation had revenue growth in 5 out of 5 years, indicating consistent revenue performance

IRadimed Corporation had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

IRadimed Corporation is overvalued relative to its fair value price of 27.87 based on Discounted Cash Flow model

IRadimed Corporation has an earnings yield of 2.00%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

IRadimed Corporation is overvalued relative to its fair value price of 19.63 based on EBITDA multiple model

IRadimed Corporation has an EV/EBITDA ratio of 35.87x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

IRadimed Corporation is overvalued relative to its fair value price of 37.13 based on Earnings Fair Value model

IRadimed Corporation has a PEG-ratio under 1 which is considered undervalued

IRadimed Corporation has a price-to-book ratio of 11.34x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

IRadimed Corporation has a price-to-sales ratio of 13.37x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue